Brief: Ipsen Says U.S. FDA Grants Ipsen’s IPN60340 Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
13/01/2026 17:42
Jan 13 (Reuters) - Ipsen SA IPN.PA: U.S. FDA GRANTS IPSEN’S IPN60340 (ICT01) BREAKTHROUGH THERAPY DESIGNATION IN FIRST LINE UNFIT ACUTE MYELOID LEUKEMIA IPSEN SA: TO DISCUSS DESIGN OF PHASE II/III DEVELOPMENT PLANS WITH FDA FOR IPN60340 IN H1 2026 Source text: ID:nGNX26fbMt Further company coverage: IPN.PA (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients